Install
News of the Day Anticipated therapies and not-so-anticipated dominate July PBAC agenda GSK brings Melbourne discovered treatment 'home' to Australian patients New government report reveals the emerging impact of generational reform Health department quietly launches major review of blood products supply Budget reveals
- 39articles · 30d
- 14+ hour agolatest article
- Aug 17, 2026earliest in window
- 92%with images
- 132avg words
- Medical 34
- Health & Wellness 29
- Health 27
- Business & Industrial 10
- Economy, Business & Finance 5
- Finance & Business 4
- Science & Technology 4
- Human Interest 1
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Noxopharm moves lupus skin therapy toward next human trial
14+ hour, 36+ min ago (117+ words) PharmaDispatch Noxopharm moves lupus skin therapy toward next human trial Noxopharm announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful, disfiguring skin condition for which no targeted…...
Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage - BioPharmaDispatch
1+ week, 18+ hour ago (124+ words) Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage PharmaDispatch Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage Neurizon Therapeutics, the Melbourne-based biotechnology company developing…...
GSK therapy becomes first biologic subsidised for Australians with uncontrolled COPD
1+ week, 6+ day ago (161+ words) PharmaDispatch GSK therapy becomes first biologic subsidised for Australians with uncontrolled COPD Lung Foundation Australia chief executive Mark Brooke said, "Living with uncontrolled COPD can be incredibly challenging. Managing breathlessness, infections and repeated flare-ups can be a source of ongoing…...
Alterity secures option underwriting as it prepares for pivotal MSA trial
2+ week, 17+ hour ago (140+ words) PharmaDispatch Alterity secures option underwriting as it prepares for pivotal MSA trial Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of…...